Invalid and irrelevant comparisons: apples or oranges?
Graeme P
GP
Currie
Kevin
K
Carter
D000085:Acetates / Q000191:economics* / Q000627:therapeutic use; D000420:Albuterol / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D000730:Androstadienes / Q000191:economics* / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000191:economics* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis; D003521:Cyclopropanes; D004338:Drug Combinations; D000068297:Fluticasone-Salmeterol Drug Combination; D006801:Humans; D020024:Leukotriene Antagonists / Q000191:economics* / Q000627:therapeutic use; D011804:Quinolines / Q000191:economics* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012129:Respiratory Function Tests; D013440:Sulfides
D000085:Acetates; D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D004338:Drug Combinations; D000068297:Fluticasone-Salmeterol Drug Combination; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast; D000420:Albuterol